# TABLE OF CONTENTS

DIVISION OF QUALITY ASSURANCE (DQA) CONTACT INFORMATION ................................................. 3

I. INTRODUCTION ............................................................................................................................ 4

II. OVERVIEW OF THE SURVEY PROCESS ..................................................................................... 4
   A. Announced and/or Unannounced Surveys ................................................................................ 4
   B. Scheduling of Surveys .............................................................................................................. 5
   C. Survey Announcement Letter and Documents Required for Survey ........................................ 5
   D. Entrance Conference ............................................................................................................... 6
   E. Outcome Oriented Survey Process ............................................................................................ 7
   F. Information Gathering ................................................................................................................ 7
   G. Assessing Outcome or Potential Outcome .................................................................................. 11
   H. Regulatory Compliance Decision ............................................................................................. 11
   I. Exit Conference ....................................................................................................................... 12

III. POST SURVEY ............................................................................................................................ 13
   A. Explanation Of Deficiency Statements ...................................................................................... 13
   B. Development Of The Statement Of Deficiencies ..................................................................... 13
   C. Plan Of Correction (POC)/Allegation of Compliance (AOC) ................................................... 13

IV. COMPLAINTS .............................................................................................................................. 14

V. ADDITIONAL INFORMATION ...................................................................................................... 15
   A. Counting Tests: ......................................................................................................................... 15
**DIVISION OF QUALITY ASSURANCE (DQA) CONTACT INFORMATION**

**Bureau of Health Services (BHS)**  
**Licensing, Certification, CLIA Section (LCCS)**

<table>
<thead>
<tr>
<th>Bureau of Health Services</th>
<th>Licensing, Certification, CLIA Section</th>
</tr>
</thead>
</table>
| DHS / Division of Quality Assurance  
Bureau of Health Services  
P.O. Box 2969  
Madison, WI 53701-2969 | DHS / Division of Quality Assurance  
BHS / LCCS  
P.O. Box 2969  
Madison, WI 53701-2969 |
| **Fed Ex or UPS Deliveries**  
1 W. Wilson St., Rm. 450  
Madison, WI 53703 | **Fed Ex or UPS Deliveries**  
1 W. Wilson St., Rm. 450  
Madison, WI 53703 |
| Telephone: 608-266-8481  
Email: DHSWebmailDQA@dhs.wisconsin.gov  
Website: http://dhs.wisconsin.gov | Telephone: 608-261-0654  
Email: DHSDQACLIA@dhs.wisconsin.gov  
Website: Clinical Laboratory Improvement Amendments (CLIA) | Wisconsin Department of Health Services  
(https://www.dhs.wisconsin.gov/regulations/labs/introduction.htm)

**Important Links**

- Stay up-to-date with regulatory changes by signing up for DQA Email Subscription Services at: [https://www.dhs.wisconsin.gov/regulations/listserv-signup.htm](https://www.dhs.wisconsin.gov/regulations/listserv-signup.htm)
- The publication, *Survey Guide – Clinical Laboratories* (DQA publication P-01227), is available online at: [https://www.dhs.wisconsin.gov/publications/index.htm](https://www.dhs.wisconsin.gov/publications/index.htm)
This survey guide is a general reference for informational purposes. In the event of any conflict between information provided in this guide and the federal legal requirements for clinical laboratories, rely on the applicable legal requirements.

I. INTRODUCTION

The Division of Quality Assurance (DQA), Bureau of Health Services (BHS) is responsible for conducting announced or unannounced surveys of laboratories in Wisconsin to ensure that federal requirements are met as directed by Centers for Medicare and Medicaid Services (CMS). Types of surveys conducted may be recertification, initial, validation, complaint, federal monitoring, and educational surveys (e.g. for labs with a certificate of waiver as determined by CMS). The following information has been prepared to serve as a guide to the survey process for evaluating laboratories.

II. OVERVIEW OF THE SURVEY PROCESS

The purpose of the survey is to determine whether the entity meets federal Clinical Laboratory Improvement Amendments (CLIA) regulations. CMS’ objective is not only to determine the laboratory’s regulatory compliance but to also assist regulated laboratories in improving patient care by emphasizing those aspects of the regulatory provisions that have a direct impact on the laboratory’s overall test performance.

Surveys are conducted by CLIA surveyors employed by DQA. State of Wisconsin surveyors perform recertification, initial, and complaint surveys on laboratories holding a Certificate of Compliance (CoC). DQA also performs validation and, when directed by CMS, complaint surveys on laboratories holding a Certificate of Accreditation (CoA). Laboratories holding a Provider Performed Microscopy (PPM) certificate, or a Certificate of Waiver (CoW) are not routinely surveyed but may be for complaint investigations or other special surveys as directed by CMS. On occasion, CMS staff may conduct federal monitoring or complaint surveys.

A. Announced and/or Unannounced Surveys

Section 353(g)(1) of the Public Health Service Act provides for either announced or unannounced surveys. Complaint or revisit surveys, and some validation surveys, must be conducted on an unannounced basis. Surveyors performing surveys of a laboratory with a CoC will schedule initial and recertification surveys. An unannounced survey may be performed after one appointment is cancelled by the laboratory. The laboratory must be informed of this when originally notified about the survey. Surveys are to be conducted during the laboratory’s routine hours of operation. The laboratory should notify the State Agency (SA) if its laboratory operations are not conducted during usual hours of operation or only on specific days and times. The surveyor will confirm the laboratory’s certificate type and advise the laboratory to notify the SA of any changes that would necessitate a different certificate.
B. **Scheduling of Surveys**

A date and time for the survey will be established with the laboratory not more than two weeks prior to the expected survey date. If a laboratory operates more than one shift or location, survey hours may be scheduled to include a representative cross-section of shifts or locations, as necessary. Note that, depending upon the extent of the findings and laboratory preparedness, the survey process may extend throughout the day and possibly into the next day(s).

Recertification Surveys: The surveyor reviews the historical file of the laboratory and will schedule the recertification survey at least six months prior, but no earlier than 12 months prior to the expiration of the laboratory’s current certificate.

Initial Surveys: In order to permit observation of actual testing during the initial survey, the initial survey will occur at least 90 days, but no later than 12 months after the data entry of the CMS Form-116 into the federal database. If after the 90 days, a representative from the laboratory states that laboratory testing is not being performed because equipment is not ready, etc., the CLIA number will be terminated until such time testing is being performed.

C. **Survey Announcement Letter and Documents Required for Survey**

To enhance survey effectiveness and efficiency, except in the case of unannounced surveys, the following forms and the survey announcement letter will be provided to the laboratory before the scheduled survey date. The laboratory must complete the forms and return them to the surveyor prior to the onsite survey.

The following forms and laboratory records are required for the survey:

1. *Laboratory Personnel Report (CLIA)*, form CMS-209, with directions for completing or updating information, adding new personnel, or changes in positions or status, with signature of current lab director.

2. *Clinical Laboratory Improvement Amendments (CLIA) Application for Certification*, form CMS-116, with signature of current owner/operator/laboratory director. For guidance with counting tests please review section V. A. Counting Tests of this survey guide.

3. The following must be accessible and retrievable at the time of survey:
   a. Standard operating procedure manual with all laboratory policies and procedures, showing initial date of use and approval by lab director. (Include package inserts and supplemental information, as necessary.)
   b. Reference laboratory’s client services manual, if applicable.
   c. Records of tests referred to other laboratories.
   d. Personnel records, including:
      1) Diplomas, certificates, degrees
      2) Training and experience
      3) Continuing education
      4) Competency assessment (initial, semi-annual, annual)
      5) Duties and responsibilities
      6) Personnel changes
e. Quality records, including:
   1) Remedial corrective action information
   2) Calibration and calibration verification records
   3) Maintenance and function checks records, etc.
   4) Individualized quality control plans
f. Performance verification records for all test systems introduced or revised within the last two years.
g. Proficiency testing (PT) reports, including:
   1) Test runs with PT results
   2) Direct printouts (e.g., analyzer, test system printouts)
   3) Records showing review and assessment of results, corrective action, and quality assessment for ungraded or unscored and unsatisfactory results
   4) Copies of the signed PT attestation forms provided by the PT program
h. For nonwaived tests and procedures that are not listed in Subpart I, verification of test or procedure accuracy twice yearly. Quality system assessment plan and documentation for each of the analytic test systems.
   1) Policies and procedures to monitor, assess, and correct identified problems
   2) Documentation of ongoing assessment activities including:
      a. Review of the effectiveness of corrective actions,
      b. Revision of policies and procedures to prevent recurrence of problems, and
      c. Discussion of assessment reviews with staff.
i. Safety and environment records.
j. Patient testing records
   1) Requisition (Patient charts may be used.)
   2) Work records (direct printouts)
   3) Patient test reports (Patient charts may be used.)
k. List of tests currently performed in the laboratory.
l. List of duties and responsibilities assigned to each person involved in the testing process.

D. Entrance Conference

Upon entering the facility, the surveyor will present appropriate identification and introduce themselves. They will ask to meet the administrator, director, or supervisor and establish a working contact for the survey. The surveyor will require a working area for record review.

The surveyor will inform the laboratory about the survey process. The laboratory will be informed that the survey will include a tour of the facility, record review, observation, and interviews with personnel involved in the pre-analytic, analytic, and post-analytic phases of the testing process. There will also be establishment of personnel availability and discussion of approximate time frames for survey completion.
The surveyor will request that the laboratory collect any documents, records, or information that may be needed to complete the survey and solicit and answer any questions the laboratory may have concerning the survey process.

E. Outcome Oriented Survey Process

The primary objective of the survey process is to determine whether the laboratory meets the federal CLIA requirements. The surveyor meets this objective by employing an outcome-oriented survey process or approach, the intent of which is to focus the surveyor on the overall performance of the laboratory and the way it monitors itself, rather than on a methodical evaluation of each standard level regulatory requirement.

The principal focus of the outcome-oriented survey is the effect (outcome) of the laboratory’s practices on patient test results and/or patient care. The outcome-oriented survey process is intended to direct the surveyor to those requirements that will most effectively and efficiently assess the laboratory’s ability to provide accurate, reliable, and timely test results.

In the outcome-oriented survey process, the surveyor reviews and assesses the overall functioning of the laboratory and evaluates the laboratory’s ability to perform quality testing; that is, the surveyor evaluates the laboratory’s quality system. The quality system requirements in the Introduction to Subpart K and the General Laboratory, Preanalytic, Analytic, and Postanalytic Quality Assessment requirements are appropriate guides which the surveyor will use in their review of the laboratory. “Subpart K – Quality System for Nonwaived Testing”: eCFR :: 42 CFR Part 493 -- Laboratory Requirements

In the outcome-oriented survey process (OOSP), emphasis is placed on the laboratory’s quality system as well as the structures and processes throughout the entire testing process that contribute to quality test results. The surveyor selects a cross-section of information from all aspects of the laboratory’s operation for review to assess the laboratory’s ability to produce quality results. The surveyor reviews the cross-section of information to verify that the laboratory has established and implemented appropriate ongoing mechanisms for monitoring its practices and identifying and resolving problems effectively.

If the findings from the review of the laboratory’s ongoing mechanisms for ensuring quality test results are sufficient to make the determination of compliance and if the evaluation does not warrant a more in-depth review, the surveyor concludes the survey and asks if the laboratory has any questions about CLIA requirements.

F. Information Gathering

Information gathering includes observation, interviews, and record review and these are usually performed concurrently. The information gathering process is critical in the determination of quality laboratory testing. As each laboratory is unique in the services offered, the order of gathering information may be different for each survey. The timing for observing testing and the availability of staff for interview may determine the sequence of the survey.

The surveyor will verify the correction and continued compliance with previously cited deficiencies. Particular attention to deficiencies that the laboratory has failed to correct will be made.

1. Organization of the Survey. The surveyor will consider the following variables when making determinations for organizing the survey and the areas to be reviewed:
a. Purpose of the Survey
   1) Initial or recertification
   2) Complaint
   3) Follow-up and/or
   4) Validation

b. Pre-survey Information gathered
   1) Problematic PT
   2) Previous survey deficiencies
   3) Complaints and/or
   4) Enforcement actions

c. Size and Organization of the Laboratory
   1) Type of instruments/test procedures
   2) Type of information system(s)
   3) Number of supervisors and testing personnel
   4) Number of testing sites
   5) Scheduling of testing (e.g., Stat, daily, weekly shifts)
   6) Number of specialties/subspecialties
   7) Test volume (See Section V. Additional Information for test counting guidance)
   8) Record availability and/or
   9) Type of patients/clients served

2. Observation of Facilities and Processes
   a. The surveyor will observe the laboratory’s physical layout. These observations will include specimen collection and processing, “prep”, and clean-up areas, testing and reporting areas, and storage areas.
   b. Specimen integrity
   c. Quality control performance
   d. Skills and knowledge of personnel regarding:
      1) Performance of testing
      2) Evaluation of test results
      3) Identification and resolution of problems
   e. Interactions of personnel regarding:
      1) Availability of supervisor to staff
      2) Communication among personnel

3. Interviews. Surveyor will interview staff to confirm observations and obtain additional information, as necessary.

4. Record Review
   a. Surveyor will gather relevant information that will reflect the laboratory’s ability to provide quality testing from all areas of the laboratory, including records encompassing the time period since the last certification survey. There will be a
review of all new tests, new test methods, and new equipment added since the prior survey and a review of documentation relevant to as many of these factors as possible when reviewing laboratory records.

b. Surveyor reviews a cross-section of information selected from records of quality system assessment activities within each of the four systems. Surveyor reviews a cross-section of information, simultaneously assessing the laboratory’s ability to provide quality test results as well as its ability to identify and correct problems. The surveyor will further investigate any problems identified but not addressed by the laboratory’s quality system assessment. If the laboratory is failing to monitor (or effectively monitor) its own system and correct its problems, the laboratory will be directed to the requirements and the relevant sections for its particular setting.

5. Proficiency Testing (PT) Review
   a. Surveyor will review PT forms that the lab has retained with required signatures.
   b. Surveyor will verify the laboratory is appropriately enrolled and participates in a CMS-approved PT program(s) for each specialty, subspecialty, analyte, and/or test for the entire period of time the laboratory has been performing testing for each regulated test.
   c. If the laboratory has unacceptable analyte/test results or unsatisfactory performance in specialties or subspecialties since the last survey, the surveyor will review the specific records, corrective action, and any other data, such as education and training of staff associated with PT remediation. Both patient test results and quality control (QC) records will be included in the review.
   d. Surveyor will verify that the laboratory has reported results under the appropriate methodology/instrumentation used for test performance, e.g., automated vs. manual hematology.
   e. Surveyor will verify that the laboratory did not engage in inter-laboratory communications and/or refer its PT samples for testing prior to reporting results to the PT provider.
   f. Surveyor will verify that PT samples were handled, prepared, processed, examined, tested, and reported, to the extent practical, in the same manner as patient samples.
   g. For tests where there is no PT available and/or those tests performed by the laboratory that are not included in Subpart I, surveyor will determine that the laboratory verifies the accuracy of each test at least twice a year.
   h. For further Proficiency Testing information please review the PT and PT Referral brochure: CLIA Brochures | CMS

6. Facility Administration
   a. Surveyor will review records for the appropriate retention times and assure the laboratory adheres to appropriate safety, arrangement, and space, ventilation, and contamination procedures.
   b. If the facility provides transfusion services, the surveyor will verify that the arrangement/contract is current, the blood products are stored appropriately, and transfusion reactions are investigated and reported to the appropriate authorities in
a timely manner. All transfusion related fatalities must be reported to the Food and Drug Administration (FDA): Transfusion/Donation Fatalities | FDA.

7. **Quality Systems**
   a. **General Laboratory, Pre analytic, Analytic, and Post analytic System Quality Assessment.** Using the patient test requisitions, test records, test results, and test reports or, as applicable, patient charts, surveyor will review all phases of the laboratory testing processes, including instructions for specimen storage. After determining the patient population serviced by the laboratory (e.g., geriatrics, public health clinics, dialysis units, health fairs, and hospitals), review the following:
      1) A cross-section of patient test results encompassing all specialties and subspecialties of testing performed in the laboratory in sufficient numbers to determine if results vary significantly from expected population norms
      2) Worksheets or instrument printouts, looking for outliers, trends, etc. for testing performed in batches and random
      3) Test results that are disproportionately abnormal or normal
      4) The correlation of initial test results and/or test result of various analytes of a patient over time
   b. The surveyor will review QC practices and evaluate whether the laboratory is following its own QC protocols, or those procedures specified by the manufacturer. Surveyor reviews QC results, including outliers, shifts, trends, and corrective actions taken, when necessary. Individualized Quality Control Plans (IQCP) must be available and current. For further IQCP information please review the CMS IQCP brochure: CLIA Brochures | CMS
   c. Refer to the establishment and verification of performance specifications at the Code of Federal Regulations, 42 CFR 493.1253, for guidance in reviewing the laboratory’s method, test system, or analyte to its test menu. For further information please review the CMS Verification of Performance Specifications and Calibration and Calibration Verification brochures: CLIA Brochures | CMS
   d. Correlate reported patient test data with QC data and/or quality systems assessment records to ensure proper performance and documentation of controls. Review original test data (instrument printouts or computer files). Surveyor will verify that patient results have not been reported when QC data was unacceptable according to the laboratory’s protocol.

The following will be considered in relation to the laboratory’s patient population:
   1) New methodologies and equipment
   2) QC and calibration materials used
   3) Source and availability of QC limits
   4) Evaluation and monitoring of QC data
   5) Corrective action for QC failures

8. **Personnel**
   a. The scope of the review of personnel records (qualifications, training, and competency) will be related to the type of survey, type and complexity of testing performed, and the observations and findings of the survey. For **initial CLIA**
certification surveys, the qualifications and experience of the laboratory director and each technical consultant, technical supervisor, clinical consultant, general and cytology supervisor, and cytotechnologist will be evaluated. A cross-section of all of the qualifications and experience of testing personnel will be evaluated. For Laboratory Director responsibilities please review the CMS Laboratory Director brochure: [CLIA Brochures | CMS](https://www.cms.gov)

b. For CLIA recertification surveys, it is not always necessary to review personnel qualification records of individuals previously evaluated unless there have been changes in the individual’s position and/or the laboratory’s test menu since the last survey.

c. Training records are reviewed for new testing personnel or for changes of instrumentation or addition of new testing methodology. Training records and documentation of training are not the same as competency assessment.

d. Competency assessment records are reviewed for all testing personnel, technical consultants, technical supervisors, and general supervisors. Please review the CMS Competency Assessment brochure for competency assessment requirements: [CLIA Brochures | CMS](https://www.cms.gov)

G. Assessing Outcome or Potential Outcome

The surveyor will review and analyze all collected information to determine whether the laboratory has complied with applicable federal regulations. Analysis and outcome assessment is an ongoing process throughout the survey. The surveyor maintains ongoing, informal communication with the laboratory’s liaison as questions arise. Surveyors will conduct a daily report of findings if survey is more than one day in length.

If the information gathered indicates that the laboratory has established, implemented, and maintained appropriate ongoing mechanisms for ensuring quality test results by monitoring, evaluating, and resolving any problems in its practices, and the surveyor’s findings do not warrant a more in-depth review, the survey will be concluded. However, if an outcome assessment of the laboratory’s performance based on the cross-section of information collected can’t be determined, it may be necessary to expand the cross-section (e.g., number of sites, observations, number of records).

The survey process allows the surveyor freedom to increase or decrease the number and types of records reviewed, the personnel interviewed, and the observations made as individual needs are identified.

H. Regulatory Compliance Decision

After all necessary information has been collected and the outcome or potential outcome has been evaluated to determine if a preliminary finding constitutes a deficiency, determination will be made if it is a standard or condition level deficiency.

CLIA regulations are condition and standard level requirements as mandated by CLIA statute that must be met by laboratories, as applicable. The CLIA standards are designed to define component criteria constituting a CLIA condition or address a distinguishable aspect of the condition. Conditions are usually more serious and comprehensive.

The number of deficiencies does not necessarily relate to whether a condition level deficiency is found out of compliance. The determination is made based on an evaluation of
the impact or potential impact of the identified deficiencies on the quality of laboratory services and the results reported. A condition level deficiency is considered for one or more deficiencies if, in surveyor judgment, the deficiency(ies) constitutes a significant or a serious problem that adversely affects patient test results/patient care or has the potential for adversely affecting patient test results/patient care.

Immediate jeopardy is defined in 42 CFR §493.2 as “a situation in which immediate corrective action is necessary because the laboratory’s noncompliance with one or more condition level requirements has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health or safety of the general public. This term is synonymous with imminent and serious risk to human health and significant hazard to the public health.” When the possibility of immediate jeopardy exists, the surveyor consults with the state agency (SA) supervisor and CMS Chicago Location before a determination of immediate jeopardy is made.

I. Exit Conference

The purpose of the exit conference is for the surveyor to review findings with the laboratory and is not meant to be all-inclusive. It is the continuation of the educational survey process and the beginning of due process. The exit conference is the first opportunity for the laboratory to present additional information in response to the findings.

If immediate jeopardy or condition level deficiencies are identified, the laboratory will be informed of the seriousness of the problem(s)/finding(s) and indicate that they are not final and are subject to review.

The exit conference will be conducted with the facility’s administrator, director, consultant, or supervisor, and/or other invited staff. The following will be discussed:

1. The laboratory practices that are not in compliance with regulatory requirements and the findings that substantiate these deficiencies

2. Provide the laboratory an opportunity to discuss and provide additional information regarding deficiencies. It is the laboratory’s responsibility to determine the corrective actions(s) necessary to remedy the problem(s).

3. Inform the laboratory that they will receive a written statement of deficiencies (Form CMS-2567) with the final deficiencies cited.

4. Provide instructions and the time frame necessary for submitting a plan of correction (POC) or allegation of compliance (AOC). Regulatory timeframe for submission of a POC or AOC is 10 calendar days.

5. Inform the facility of the intended recommendation to CMS to certify, recertify, or deny certification of the laboratory.

6. At the exit interview, inform the laboratory (director/administrator/supervisor) of changes in test volumes which may result in fee changes.

The laboratory may have an attorney present but should give advance notice of this to the surveyor. The exit conference is an informal process and attorneys do not usually attend. Surveyors have been instructed not to answer any questions from the laboratory’s attorney.

A court reporter may not attend the exit conference. If a laboratory wishes to audio record or video tape the exit conference, it must first obtain permission from the surveyor. An
identical, simultaneous recording must be given to the surveyor at the conclusion of the exit conference.

Any eavesdropping or any audio recording or videotaping without the express knowledge and permission of the surveyor is considered impeding the survey process. This may result in termination of the survey.

III. POST SURVEY

A. Explanation Of Deficiency Statements

The surveyor summarizes the survey findings in a written final report. If the surveyor determines that the laboratory is out of compliance with regulations, the surveyor will document those findings. The findings serve as a basis for the laboratory to analyze its deficient practices or system failures and develop plans of correction. Survey findings are documented on the Statement of Deficiencies (SOD), form CMS-2567. Survey findings are sent via certified mail or electronically within 10 days following the exit conference.

B. Development Of The Statement Of Deficiencies

A violation exists when a laboratory fails to comply with a federal regulation. The Department of Health Services promulgates and enforces rules and standards necessary to provide safe and adequate care and treatment of patients and to protect the health and safety of patients and employees of laboratories. The department authority is derived from CLIA regulations at 42 CFR Part 493.

The surveyor will choose the most appropriate regulatory citation when documenting a deficiency.

1. **Standard Level Deficiencies.** If noncompliance has been identified, cite the most specific standard available.

2. **Condition Level Deficiencies.** When the deficient practice is of such a serious nature that correction is necessary for the laboratory’s testing to continue, cite the most appropriate condition. The laboratory must correct those standard level deficiencies that are used to support the condition level noncompliance before the condition can be considered back in compliance.

C. Plan Of Correction (POC)/Allegation of Compliance (AOC)

If, after receiving a SOD, there are questions regarding the survey findings, the laboratory may consult informally with the surveyor or surveyor’s supervisor to discuss compliance.

The webpage linked below outlines the DQA electronic process for submission of SODs, POCs, and AOCs: [https://www.dhs.wisconsin.gov/regulations/e-sod.htm](https://www.dhs.wisconsin.gov/regulations/e-sod.htm)

If opening emails or attachments proves difficult, the previous link also has instructions for viewing encrypted messages.

1. **Content**

   To be considered complete, each Plan of Correction (POC) or Allegation of Compliance (AOC) must include the following:
a. Documentation showing what corrective action(s) have been taken for patients found to have been affected by the deficient practice
b. How the laboratory has identified other patients having the potential to be affected by the same deficient practice and what corrective action(s) has/have been taken
c. What measure has been put into place or what systemic changes have been made to ensure that the deficient practice does not recur
d. Who will be responsible for ensuring corrective action is monitored and how this monitoring will be performed in order to ensure the deficient practice does not recur.

Use of personal names in a Plan of Correction / Allegation of Compliance will be cause for rejection. As needed, position titles or other suitable descriptors should be used.

2. Correction of Violations
A laboratory is requested to submit a plan to correct the violations (Plan of Correction for standard level deficiencies or Allegation of Compliance for condition level deficiencies). The laboratory shall submit a plan of correction within 10 calendar days following receipt of the Statement of Deficiencies.

If a laboratory does not provide a timely response to this request or, if the laboratory submits a Plan of Correction that is not acceptable in content and time frames or, if the laboratory does not demonstrate compliance with all CLIA requirements by the specified completion date, DQA may recommend to CMS the imposition of principal sanctions, i.e. suspension, limitation and/or revocation of the laboratory’s CLIA certificate and concurrent cancellation of the laboratory’s approval for Medicare payments per 42 CFR 493.1816.

3. Verification of Corrections
Regulations at 42 CFR 493.1816 state that if a laboratory has deficiencies that are not at the condition level, the laboratory must submit a Plan of Correction that is acceptable to CMS in content and time frames. The laboratory is required to respond within 10 calendar days of receipt of the Statement of Deficiencies. Further, regulations at 42 CFR 493.1816 require all standard level deficiencies to be corrected within 12 months after the last day of the survey. It is important to note that, depending upon the nature and seriousness of the deficiency, the acceptable time frame for correction may be less than 12 months. For condition level deficiencies, the laboratory must submit documented evidence of compliance to verify that the corrections have been made.

The surveyor will verify correction of all deficiencies during the next survey event. If there are condition level deficiencies, acceptable evidence of correction must be submitted with the AOC. A follow-up survey on condition level deficiencies may occur.

IV. COMPLAINTS

The Bureau of Health Services / Licensing, Certification, and CLIA Section receives complaints and conducts complaint surveys for laboratory practice concerns. To submit a complaint regarding laboratories:

- Call the toll-free complaint line at: 1-800-642-6552
- File a complaint online at: https://www.dhs.wisconsin.gov/guide/complaints.htm
- Write a letter and mail it to: DHS / Division of Quality Assurance
V. ADDITIONAL INFORMATION

A. Counting Tests:

Total annual volume for waived tests, if any, should be recorded on the CLIA application (Form CMS-116) in the waived testing section. The total annual volume for nonwaived tests, including PPM procedures, should be reported on the form in the Nonwaived Testing section by specialty and subspecialty. Only tests that are ordered and reported should be included in the laboratory’s test volume(s). Calculations (e.g., A/G ratio, MCH, MCHC, HCT, and T7), QC tests, and PT assays should not be counted.

1. For chemistry tests, each non-calculated analyte is counted separately (e.g., Lipid Panel consisting of a total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides equals 4 tests).
2. For complete blood counts, each measured individual analyte that is ordered and reported is counted separately. Differentials count as one test.
3. For urinalysis, microscopic and macroscopic examinations each count as one test. Macroscopics (dipsticks) are counted as one test regardless of the number of reagent pads on the strip.
4. For microbiology, susceptibility testing is counted as one test per group of antibiotics used to determine sensitivity for one organism. Cultures are counted as one per test request from each specimen regardless of the extent of identification, number of organisms isolated, and number of tests/procedures required for identification. Each gram stain or acid-fast bacteria (AFB) smear requested from the primary source is counted as one. For example, if a sputum specimen has a routine bacteriology culture and gram stain, a mycology test, and an AFB smear and culture ordered, this would be counted as five tests. For parasitology, the direct smear and the concentration and prepared slide are counted as one test.
5. For allergy testing, each allergen is counted as one test. • For flow cytometry, each measured individual analyte (e.g. T cells, B cells, CD4, etc.) that is ordered and reported should be counted separately.
6. For manual gynecologic and nongynecological cytology, each slide (not case) is counted as one test. Refer to D5643 for counting non-gynecological slide preparations using liquid-based slide preparatory techniques. Refer to D5665 for counting gynecologic cytology slide preparations when using automated and semi-automated screening devices.
7. For immunohematology, each ABO, Rh, antibody screen, cross match, or antibody identification is counted as one test.
8. For histocompatibility, each HLA typing (including disease associated antigens) is counted as one test, each HLA antibody screen is counted as one test and each HLA cross match is counted as one test. For example, a B-cell, a T-cell, and an auto-crossmatch between the same donor and recipient pair would be counted as 3 tests.

9. For histopathology, each block (not slide) is counted as one test. Autopsy services are not included. For those laboratories that perform special stains on histology slides, the test volume is determined by adding the number of special stains, including immunohistochemistry, performed on slides to the total number of specimen blocks prepared by the laboratory.

10. For cytogenetics, the number of tests is determined by the number of specimen types processed on each patient (e.g., a bone marrow and a venous blood specimen received on one patient are counted as two tests). NOTE: For all other genetic tests, the number of tests is determined by the number of results reported in the final report.

11. Genetics tests should be placed in the specialty or subspecialty where they fit best, according to the methodology of the test.